Tryptophanol

Tryptophanol

SCHEMBL81822

N[C@H](CO)Cc1c[nH]c2ccccc12

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.71
HTR1D P28221 2/20 0.66
HTR1B P28222 2/20 0.66
HTR2C P28335 2/20 0.66
HTR7 P34969 2/20 0.66
HTR6 P50406 2/20 0.66
ADRB1 P08588 1/20 0.66
HTR1A P08908 1/20 0.66
ADRA2A P08913 1/20 0.66
SLC6A2 P23975 1/20 0.66
HTR1E P28566 1/20 0.66
SLC6A4 P31645 1/20 0.66
HTR2B P41595 1/20 0.66
SLC6A3 Q01959 1/20 0.66
MAPT P10636 3/20 0.63
KDM4E B2RXH2 2/20 0.63
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
MPO P05164 2/20 0.63
PMP22 Q01453 2/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tryptophanol SCHEMBL1177116 1.00 HTR2A (0.71) HTR2AHTR1DHTR1BHTR2CHTR7
Tryptophanol SCHEMBL143812 1.00 HTR2A (0.71) HTR2AHTR1DHTR1BHTR2CHTR7
Tryptophanol SCHEMBL29401346 1.00 HTR2A (0.71) HTR2AHTR1DHTR1BHTR2CHTR7
Tryptophanol SCHEMBL4905367 0.98 HTR2A (0.69) HTR2AHTR1DHTR1BHTR2CHTR7
Tryptophanol SCHEMBL5374423 0.93 KDM4E (0.68) HTR2AHTR1DHTR1BHTR2CHTR7
Tryptophanol SCHEMBL5374419 0.93 KDM4E (0.68) HTR2AHTR1DHTR1BHTR2CHTR7
SCHEMBL4666144 0.87 HTR2A (0.68) HTR2AHTR1DHTR1BHTR2CHTR7
SCHEMBL4666066 0.87 HTR2A (0.68) HTR2AHTR1DHTR1BHTR2CHTR7
SCHEMBL4666059 0.87 HTR2A (0.68) HTR2AHTR1DHTR1BHTR2CHTR7
SCHEMBL29486333 0.85 HTR2A (0.69) HTR2AHTR1DHTR1BHTR2CHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 822 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120195409-A Composition for diagnosing sepsis and medicament for sepsis preventive treatment 北京大学第三医院(北京大学第三临床医学院) 2025-06-24 CN claimed
CN-120058554-A Epoxy curing agent containing double dynamic bonds, preparation method thereof, degradable and reconfigurable epoxy resin material and preparation method thereof 西安智聚复合材料科技有限公司 2025-05-30 CN claimed
WO-2025019172-A1 ANTIMICROBIAL EXTRACTANT FORMED FROM COPPER-CONTAINING SOURCE CORNING INCORPORATED (US) 2025-01-23 WO claimed
CN-119023977-A Method for early diagnosis of motor muscle micro-injury by using urine metabolite type biomarker 北京理工大学 2024-11-26 CN claimed
CN-118831098-A Climbing sand worm effective part extract with diuretic effect and application thereof 西南民族大学 2024-10-25 CN claimed
CN-116730898-A Synthesis method of L-tryptophanol 荟达医药科技(上海)有限公司 2023-09-12 CN claimed
WO-2023284262-A1 3,4-FUSED SEVEN-MEMBERED HETEROCYCLIC OXINDOLE, SYNTHESIS METHOD THEREFOR AND APPLICATION THEREOF 青岛农业大学 2023-01-19 WO claimed
CN-109187792-B Tryptophanol and xanthosine in urine as diagnostic markers of idiopathic male infertility and application thereof 南京医科大学 2022-04-08 CN claimed
CN-111819217-B Amphiphilic block copolymer, preparation method thereof and nano micelle drug loading system 张富尧 2021-10-01 CN claimed
CN-111819217-A Amphiphilic block copolymer, preparation method thereof and nano micelle drug loading system 上海时莱生物技术有限公司 2020-10-23 CN claimed
US-20070060573-A1 Acyltryptophanols BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-03-15 US claimed
WO-2007017289-A2 ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-02-15 WO claimed
WO-2006010278-A1 BIOCOMPATIBLE, BIODEGRADABLE POLYURETHANE MATERIALS WITH CONTROLLED HYDROPHOBIC TO HYDROPHILIC RATIO SYNTHES GMBH (CH) 2006-02-02 WO claimed
EP-1568770-A2 Pharmaceutical use of compounds which bind to a mammalian \"trace amine\" receptor Oregon Health & Science University (US) 2005-08-31 EP claimed
US-20040072187-A1 Novel mammalian receptor genes and uses OREGON HEALTH & SCIENCE UNIVERSITY 2004-04-15 US claimed
WO-2004020402-A1 SULPHONYLAMINO DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE DE NOVO PHARMACEUTICALS LIMITED (GB) 2004-03-11 WO claimed
WO-2002022801-A9 MAMMALIAN RECEPTOR GENES AND USES UNIV OREGON HEALTH & SCIENCE (US) 2003-07-03 WO claimed
EP-1319070-A2 MAMMALIAN RECEPTOR GENES AND USES Oregon Health & Science University (US) 2003-06-18 EP claimed
WO-2002022801-A2 MAMMALIAN RECEPTOR GENES AND USES OREGON HEALTH & SCIENCE UNIVERSITY (US) 2002-03-21 WO claimed
EP-0124388-A1 Strain of Trichoderma harzianum, process for its isolation, process for its culture, peptides or compounds produced by this strain and application of this strain and these peptides or the product produced by the culture process as a means for biological control in the form of a phytosanitary product LES PRODUITS ORGANIQUES DU SANTERRE ORSAN (FR) 1984-11-07 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060573-A1 Acyltryptophanols FSHR, NPY1R, NPY2R HTR2A 11/4885HTR1D 25/4885HTR1B 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.